BRISTOL MYERS SQUIBB CO (BMY)
Every FINRA and SEC series the site collects for BRISTOL MYERS SQUIBB CO: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on NYSE, classified by the SEC as pharmaceutical preparations.
45.9M
Short interest
settlement 2026-08-14
3.5
Days to cover
-12.4% vs prior
51.8%
Short share of volume
2026-09-11
301
Fails to deliver
settlement 2026-08-13
-$437K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in BMY is 45,852,662 shares, up 917,300 shares over the last month. Over the last 48 readings it ranged from 20,033,587 shares (30 September 2024) to 52,336,079 shares (31 July 2026). At the reported average volume of 13.2M shares a day that is 3.5 days to cover.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/bmy" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 45,852,662 | -12.4% | 13,183,281 | 3.48 |
| 2026-07-31 | 52,336,079 | +16.5% | 11,294,121 | 4.63 |
| 2026-07-15 | 44,935,362 | +10.9% | 10,603,478 | 4.24 |
| 2026-06-30 | 40,531,289 | +2.4% | 16,383,235 | 2.47 |
| 2026-06-15 | 39,595,308 | +2.8% | 11,894,736 | 3.33 |
| 2026-05-29 | 38,507,952 | +4.9% | 11,144,361 | 3.46 |
| 2026-05-15 | 36,716,099 | +17.2% | 10,381,700 | 3.54 |
| 2026-04-30 | 31,330,595 | -3.3% | 9,871,549 | 3.17 |
| 2026-04-15 | 32,393,759 | +2.8% | 9,465,589 | 3.42 |
| 2026-03-31 | 31,501,585 | +5.5% | 15,833,195 | 1.99 |
| 2026-03-13 | 29,852,257 | -10.7% | 11,789,104 | 2.53 |
| 2026-02-27 | 33,420,961 | +5.5% | 13,016,834 | 2.57 |
| 2026-02-13 | 31,674,440 | +6.0% | 14,615,157 | 2.17 |
| 2026-01-30 | 29,894,882 | -19.1% | 12,741,067 | 2.35 |
| 2026-01-15 | 36,975,176 | +1.1% | 12,869,177 | 2.87 |
| 2025-12-31 | 36,577,723 | +3.2% | 16,091,811 | 2.27 |
| 2025-12-15 | 35,431,255 | +4.5% | 16,391,235 | 2.16 |
| 2025-11-28 | 33,891,065 | +7.0% | 14,281,206 | 2.37 |
| 2025-11-14 | 31,685,786 | -1.2% | 14,120,523 | 2.24 |
| 2025-10-31 | 32,070,775 | +5.6% | 17,797,730 | 1.80 |
| 2025-10-15 | 30,358,285 | +15.2% | 17,889,611 | 1.70 |
| 2025-09-30 | 26,343,569 | -10.6% | 19,180,880 | 1.37 |
| 2025-09-15 | 29,470,983 | -5.5% | 9,460,298 | 3.12 |
| 2025-08-29 | 31,193,823 | +5.1% | 9,732,383 | 3.21 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of BMY volume is 51.8%, down 2.2 points over the last five sessions. Over the last 52 readings it ranged from 31.0% (12 August 2026) to 68.8% (14 July 2026). The latest reading is in line with the 30-session average of 50.4%, on 2.2M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 1.2M | 2.2M | 51.8% | 1,688 |
| 2026-09-10 | 1.1M | 2.1M | 54.0% | 3,950 |
| 2026-09-09 | 997K | 1.9M | 52.5% | 3,624 |
| 2026-09-08 | 1.7M | 2.7M | 60.5% | 1,183 |
| 2026-09-04 | 955K | 1.6M | 58.0% | 1,058 |
| 2026-09-03 | 988K | 1.8M | 54.0% | 9,130 |
| 2026-09-02 | 1.1M | 2.0M | 55.9% | 3,410 |
| 2026-09-01 | 1.1M | 2.2M | 49.8% | 3,679 |
| 2026-08-31 | 1.1M | 2.0M | 56.5% | 1,996 |
| 2026-08-28 | 928K | 1.7M | 55.2% | 1,434 |
| 2026-08-27 | 813K | 1.6M | 50.6% | 0 |
| 2026-08-26 | 1.3M | 2.0M | 64.6% | 7,401 |
| 2026-08-25 | 1.4M | 2.3M | 61.3% | 20,575 |
| 2026-08-24 | 1.0M | 1.9M | 54.2% | 2,160 |
| 2026-08-21 | 1.0M | 2.1M | 49.2% | 3,486 |
| 2026-08-20 | 1.1M | 3.0M | 35.4% | 2,257 |
| 2026-08-19 | 2.0M | 4.0M | 51.2% | 7,420 |
| 2026-08-18 | 1.3M | 2.8M | 48.1% | 5,148 |
| 2026-08-17 | 1.0M | 2.2M | 47.7% | 621 |
| 2026-08-14 | 1.2M | 2.4M | 51.4% | 3,308 |
| 2026-08-13 | 2.2M | 4.0M | 53.7% | 5,499 |
| 2026-08-12 | 1.0M | 3.3M | 31.0% | 3,866 |
| 2026-08-11 | 1.7M | 3.0M | 56.5% | 9,253 |
| 2026-08-10 | 1.4M | 2.8M | 47.5% | 556 |
| 2026-08-07 | 1.1M | 2.2M | 48.7% | 1,334 |
| 2026-08-06 | 1.3M | 3.0M | 44.5% | 2,837 |
| 2026-08-05 | 2.2M | 4.6M | 48.3% | 9,197 |
| 2026-08-04 | 2.9M | 8.8M | 33.3% | 20,468 |
| 2026-08-03 | 4.5M | 11.9M | 37.9% | 44,204 |
| 2026-07-31 | 2.2M | 4.4M | 49.0% | 4,778 |
Fails to deliver
SEC, by settlement date. JSONAs of 13 August 2026, the fails-to-deliver balance in BMY is 301 shares, up 271 shares over the last settlement date. Over the last 52 readings it ranged from 15 shares (5 January 2026) to 393,782 shares (17 December 2025). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-13 | 301 | $63.70 | $19K |
| 2026-08-03 | 30 | $65.31 | $2K |
| 2026-07-31 | 62,638 | $64.86 | $4.1M |
| 2026-07-29 | 175 | $63.60 | $11K |
| 2026-07-24 | 734 | $61.51 | $45K |
| 2026-07-22 | 361 | $60.93 | $22K |
| 2026-07-21 | 2,346 | $60.16 | $141K |
| 2026-07-20 | 11,818 | $60.74 | $718K |
| 2026-07-02 | 965 | $56.44 | $54K |
| 2026-06-30 | 2,336 | $58.56 | $137K |
| 2026-06-25 | 347,899 | $55.00 | $19.1M |
| 2026-06-22 | 7,786 | $54.00 | $420K |
| 2026-06-05 | 545 | $56.60 | $31K |
| 2026-06-02 | 27,657 | $54.95 | $1.5M |
| 2026-04-29 | 7,119 | $58.26 | $415K |
| 2026-04-23 | 5,060 | $58.80 | $298K |
| 2026-04-22 | 1,350 | $59.39 | $80K |
| 2026-04-20 | 16,428 | $60.17 | $988K |
| 2026-04-15 | 15 | $58.08 | $871 |
| 2026-04-14 | 15,100 | $58.06 | $877K |
| 2026-04-09 | 170 | $59.20 | $10K |
| 2026-04-08 | 529 | $57.67 | $31K |
| 2026-04-02 | 17,500 | $61.73 | $1.1M |
| 2026-03-25 | 1,467 | $57.39 | $84K |
| 2026-03-03 | 18,998 | $62.34 | $1.2M |
| 2026-02-27 | 30 | $61.10 | $2K |
| 2026-02-26 | 1,118 | $61.30 | $69K |
| 2026-02-23 | 32,117 | $60.66 | $1.9M |
| 2026-02-18 | 33,995 | $60.35 | $2.1M |
| 2026-02-10 | 11,101 | $60.77 | $675K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at BMY reported 2 open-market sells worth $437K in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Massacesi Cristian (EVP,Chief Med Offr,Head of Dev) on 2026-09-09.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | Sell | 6K | $64.57 | $403K | 19K |
| 2026-09-01 | Short Bartie Wendy | EVP, Corporate Affairs | Tax withholding | 633 | $66.92 | $42K | 13K |
| 2026-09-01 | Short Bartie Wendy | EVP, Corporate Affairs | Option exercise | 1K | $66.92 | $83K | 13K |
| 2026-08-25 | Holzer Phil M | SVP and Controller | Sell | 500 | $67.50 | $34K | 17K |
| 2026-08-01 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | Tax withholding | 26K | $65.31 | $1.7M | 25K |
| 2026-08-01 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | Option exercise | 51K | $0.00 | $0 | 51K |
| 2026-08-01 | Gallman Cari | EVP, General Counsel | Tax withholding | 543 | $65.31 | $35K | 14K |
| 2026-08-01 | Gallman Cari | EVP, General Counsel | Option exercise | 1K | $0.00 | $0 | 14K |
| 2026-06-15 | Haller Julia A | n/a | Option exercise | 20K | $53.76 | $1.1M | 34K |
| 2026-06-03 | Short Bartie Wendy | EVP, Corporate Affairs | Tax withholding | 4K | $54.72 | $212K | 12K |
| 2026-06-03 | Short Bartie Wendy | EVP, Corporate Affairs | Option exercise | 8K | $0.00 | $0 | 16K |
| 2026-05-01 | Lenkowsky Adam | EVP, Chief Commercial Officer | Tax withholding | 599 | $58.22 | $35K | 20K |
| 2026-05-01 | Lenkowsky Adam | EVP, Chief Commercial Officer | J | 203 | $0.00 | $0 | 20K |
| 2026-05-01 | Lenkowsky Adam | EVP, Chief Commercial Officer | Option exercise | 1K | $0.00 | $0 | 21K |
| 2026-04-01 | Shanahan Karin | EVP, Chief Supply Chain & Ops | Tax withholding | 2K | $61.73 | $104K | 26K |
| 2026-04-01 | Shanahan Karin | EVP, Chief Supply Chain & Ops | Option exercise | 3K | $0.00 | $0 | 28K |
| 2026-04-01 | Elkins David V | EVP, Chief Financial Officer | Sell | 4K | $62.05 | $278K | 159K |
| 2026-04-01 | Elkins David V | EVP, Chief Financial Officer | Sell | 26K | $61.60 | $1.6M | 164K |
| 2026-03-10 | Short Bartie Wendy | EVP, Corporate Affairs | Tax withholding | 828 | $60.13 | $50K | 8K |
| 2026-03-10 | Short Bartie Wendy | EVP, Corporate Affairs | J | 2K | $0.00 | $0 | 9K |
| 2026-03-10 | Short Bartie Wendy | EVP, Corporate Affairs | Option exercise | 4K | $0.00 | $0 | 11K |
| 2026-03-10 | Short Bartie Wendy | EVP, Corporate Affairs | Tax withholding | 242 | $60.13 | $15K | 6K |
| 2026-03-10 | Short Bartie Wendy | EVP, Corporate Affairs | J | 81 | $0.00 | $0 | 7K |
| 2026-03-10 | Short Bartie Wendy | EVP, Corporate Affairs | Option exercise | 749 | $0.00 | $0 | 7K |
| 2026-03-10 | Short Bartie Wendy | EVP, Corporate Affairs | Tax withholding | 205 | $60.13 | $12K | 6K |
| 2026-03-10 | Short Bartie Wendy | EVP, Corporate Affairs | J | 72 | $0.00 | $0 | 6K |
| 2026-03-10 | Short Bartie Wendy | EVP, Corporate Affairs | Option exercise | 639 | $0.00 | $0 | 6K |
| 2026-03-10 | Holzer Phil M | SVP and Controller | Tax withholding | 849 | $60.13 | $51K | 17K |
| 2026-03-10 | Holzer Phil M | SVP and Controller | J | 2K | $0.00 | $0 | 18K |
| 2026-03-10 | Holzer Phil M | SVP and Controller | Option exercise | 5K | $0.00 | $0 | 20K |
| 2026-03-10 | Holzer Phil M | SVP and Controller | Tax withholding | 248 | $60.13 | $15K | 16K |
| 2026-03-10 | Holzer Phil M | SVP and Controller | J | 83 | $0.00 | $0 | 16K |
| 2026-03-10 | Holzer Phil M | SVP and Controller | Option exercise | 768 | $0.00 | $0 | 16K |
| 2026-03-10 | Holzer Phil M | SVP and Controller | Tax withholding | 261 | $60.13 | $16K | 15K |
| 2026-03-10 | Holzer Phil M | SVP and Controller | J | 91 | $0.00 | $0 | 16K |
| 2026-03-10 | Holzer Phil M | SVP and Controller | Option exercise | 811 | $0.00 | $0 | 16K |
| 2026-03-10 | Hoch Lynelle | President, Cell Therapy Org. | Tax withholding | 912 | $60.13 | $55K | 8K |
| 2026-03-10 | Hoch Lynelle | President, Cell Therapy Org. | J | 3K | $0.00 | $0 | 9K |
| 2026-03-10 | Hoch Lynelle | President, Cell Therapy Org. | Option exercise | 6K | $0.00 | $0 | 12K |
| 2026-03-10 | Hoch Lynelle | President, Cell Therapy Org. | Tax withholding | 267 | $60.13 | $16K | 6K |
| 2026-03-10 | Hoch Lynelle | President, Cell Therapy Org. | J | 113 | $0.00 | $0 | 6K |
| 2026-03-10 | Hoch Lynelle | President, Cell Therapy Org. | Option exercise | 1K | $0.00 | $0 | 6K |
| 2026-03-10 | Hoch Lynelle | President, Cell Therapy Org. | Tax withholding | 212 | $60.13 | $13K | 5K |
| 2026-03-10 | Hoch Lynelle | President, Cell Therapy Org. | J | 94 | $0.00 | $0 | 5K |
| 2026-03-10 | Hoch Lynelle | President, Cell Therapy Org. | Option exercise | 838 | $0.00 | $0 | 6K |
| 2026-03-10 | Poole Ahn Amanda | EVP, Chief People Officer | Tax withholding | 1K | $60.13 | $76K | 7K |
| 2026-03-10 | Poole Ahn Amanda | EVP, Chief People Officer | J | 2K | $0.00 | $0 | 8K |
| 2026-03-10 | Poole Ahn Amanda | EVP, Chief People Officer | Option exercise | 5K | $0.00 | $0 | 11K |
| 2026-03-10 | Poole Ahn Amanda | EVP, Chief People Officer | Tax withholding | 367 | $60.13 | $22K | 6K |
| 2026-03-10 | Poole Ahn Amanda | EVP, Chief People Officer | J | 87 | $0.00 | $0 | 6K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for BMY worth $437K at the prices reported; 2 in the last 90 days worth $437K. Latest: Massacesi Cristian filed on 2026-09-09 to sell 6,249 shares ($403K) from 2026-09-09.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-09 | Massacesi CristianOfficer | 6K | $403K | 0.000% | 2026-09-09 | Fidelity Brokerage Services LLC |
| 2026-08-25 | Holzer Phil MOfficer | 500 | $34K | 0.000% | 2026-08-25 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON1 holder above 5% has filed on BMY, all on Schedule 13G (passive). The largest reported stake is STATE STREET CORPORATION at 5.0% of the class (102,521,748 shares), filed 2026-08-07 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 102.5M | 5.0% | 2026-06-30 |
13F holders
Tracked managers holding BMY at their latest 13F. JSON7 of the 30 tracked managers held BMY at their latest 13F, $2.87B in total at quarter-end prices. AQR Capital Management is the largest at $1.58B (0.5% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 5 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 27.4M | $1.58B | 0.55% | -2.3M |
| Two Sigma Investments | 2026-06-30 | 10.1M | $581.5M | 0.42% | -1.5M |
| Citadel Advisors | 2026-06-30 | 7.7M | $442.9M | 0.05% | -1.8M |
| D. E. Shaw & Co. | 2026-06-30 | 1.7M | $97.0M | 0.05% | +624K |
| Millennium Management | 2026-06-30 | 1.5M | $86.4M | 0.03% | -3.0M |
| Point72 Asset Management | 2026-06-30 | 1.4M | $78.3M | 0.09% | +259K |
| Fisher Asset Management | 2026-06-30 | 173K | $10.0M | 0.00% | -30K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) BRISTOL MYERS SQUIBB CO reported revenue of $12.97B, up 5.7% from the same quarter a year earlier, and net income of $3.32B (1.62 diluted EPS). In FY 2025 it generated $14.16B of operating cash flow and spent $5.04B on dividends. As of 2026-06-30, cash was $8.72B against $42.86B of debt.
- Cash
- $8.72B
- Debt
- $42.86B
- Equity
- $22.32B
- Total assets
- $87.63B
- Shares outstanding
- 2,042,714,656
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.97B | $3.32B | 25.6% | 1.62 |
| Q1 2026 | 2026-03-31 | $11.49B | $2.68B | 23.3% | 1.31 |
| Q4 2025derived | 2025-12-31 | $12.50B | $1.09B | 8.7% | n/a |
| Q3 2025 | 2025-09-30 | $12.22B | $2.20B | 18.0% | 1.08 |
| Q2 2025 | 2025-06-30 | $12.27B | $1.31B | 10.7% | 0.64 |
| Q1 2025 | 2025-03-31 | $11.20B | $2.46B | 21.9% | 1.20 |
| Q4 2024derived | 2024-12-31 | $12.34B | $72.0M | 0.6% | n/a |
| Q3 2024 | 2024-09-30 | $11.89B | $1.21B | 10.2% | 0.60 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $48.19B | $7.05B | $14.16B | $1.31B | $0 | $5.04B |
| FY 2024 | 2024-12-31 | $48.30B | -$8.95B | $15.19B | $1.25B | $0 | $4.86B |
| FY 2023 | 2023-12-31 | $45.01B | $8.03B | $13.86B | $1.21B | $5.16B | $4.74B |
| FY 2022 | 2022-12-31 | $46.16B | $6.33B | $13.07B | $1.12B | $8.00B | $4.63B |
| FY 2021 | 2021-12-31 | $46.38B | $6.99B | $16.21B | $973.0M | $6.29B | $4.40B |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-22 from the cover page.
What this page is
BRISTOL MYERS SQUIBB CO in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows BRISTOL MYERS SQUIBB CO (BMY), SEC CIK 14272, listed on NYSE, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-09.JSON and CSV
- Company record
- EDGAR filing index for CIK 14272Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUNITED THERAPEUTICS Corp
- CPIXCUMBERLAND PHARMACEUTICALS INC
- LLYELI LILLY & Co
- ALNYALNYLAM PHARMACEUTICALS, INC.
- PTCTPTC THERAPEUTICS, INC.
- MDGLMADRIGAL PHARMACEUTICALS, INC.
- ONCBeOne Medicines Ltd.
- IONSIONIS PHARMACEUTICALS INC
- INSMINSMED Inc
- CORTCORCEPT THERAPEUTICS INC
- ROIVRoivant Sciences Ltd.
- BBIOBridgeBio Pharma, Inc.
- CYTKCYTOKINETICS INC
- LGNDLIGAND PHARMACEUTICALS INC
- VRTXVERTEX PHARMACEUTICALS INC / MA
- LQDALiquidia Corp
- SIONSionna Therapeutics, Inc.
- JAZZJazz Pharmaceuticals plc
- BLTEBELITE BIO, INC
- TVTXTravere Therapeutics, Inc.
- PAHCPHIBRO ANIMAL HEALTH CORP
- ARQTArcutis Biotherapeutics, Inc.
- NATRNATURES SUNSHINE PRODUCTS INC
- HOWLWerewolf Therapeutics, Inc.
Datasets
Frequently Asked Questions
How much of BMY is sold short?
What is BMY's daily short volume?
Does BMY have fails to deliver?
Are BMY insiders buying or selling?
Have BMY insiders filed to sell?
Who owns more than 5% of BMY?
What did BMY report last quarter?
Which funds hold BMY?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.